Clinical Trial

Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis

Study acronym: STOPGAP
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II clinical trial assessing the safety and efficacy of sequential systemic and intraperitoneal (IP) chemotherapy in patients with primary gastric/gastroesophageal junction cancer with cytology positive peritoneal lavage and/or peritoneal carcinomatosis.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2021-02-17; most recent amendment 2026-01-30.
Status change: Recruiting → Active, Not Recruiting 2026-01-30
Status change: Not Yet Recruiting → Recruiting 2021-03-05
Trial Details
NCT Number NCT04762953
Lead Sponsor University of California, Irvine
Conditions Gastric Cancer, Peritoneal Carcinomatosis, Gastroesophageal Junction Adenocarcinoma
Enrollment 40 participants
Start Date 2021-02-18
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-03